PSVT, 1) placebo. flecainide PAF, treatment PAF or Number w/ no periods (5 pts parosysmal tachycardia in Group 1 and atrial atrial flutter increased w/ 6 pts in Group flutter (n=28, Group progressively 2). 2) larger flecainide doses; w/ the 150 mg twice daily dose, 12 (86%) of 14 pts had no tachycardia (p<0.01 for overall differences among all treatments). Oral 23 Propafenone Placebo PSVT Angina during Compared w/ Cardiac AEs HR during N/A Propafenone 1991 (n=23) (n=23) (n=14) tachycardia, placebo, occurred only in recurrences, efficacious in (28) to pulmonary edema, propafenone pts w/ PAF and not treating PSVT prevent PAF neurologic caused an (9/11): 2 w/ statistically and PAF. (n=9) sxs. increase in prolonged different PAF w/ WPW, on time to first episode of AF, between Major PSVT AADs recurrence of 1 w/ atrial flutter propafenone limitation in arrhythmia w/ a mean and placebo not knowing (p=0.004) ventricular how many pts rate of 263 bpm had AVNRT. PSVT: recorded using . blind, p=0.03 the telephone monitor. PAF: d, p=0.06 . phase, w/ each period lasting up to 60 d. 49 PSVT Placebo Pts enrolled from 3 Syncope, angina, or -Number of No pt N/A N/A Supports n (n=21) prior studies transient cerebral pts w/o experienced flecainide for 1994 efficacy evaluating short-term events during PSVT, attacks proarrhythmia, chronic (29) of PAF flecainide efficacy second or third -Time to first MI, or died therapy of (n=28) degree AV block or attack during chronic PSVT. (≥6 had CHF (NYHA -Interval efficacy study.
PSVT, PAF, atrial flutter 1) PAF or parosysmal atrial flutter (n=28, Group 2) placebo. Number w/ no tachycardia increased w/ progressively larger flecainide doses; w/ the 150 mg twice daily dose, 12 (86%) of 14 pts had no tachycardia (p<0.01 for overall differences among all treatments). flecainide treatment periods (5 pts in Group 1 and 6 pts in Group 2). 1991 (28) Oral to prevent PSVT phase, w/ each period lasting up to 60 d. 23 Propafenone (n=23) Placebo (n=23) PSVT (n=14) PAF (n=9) Angina during tachycardia, pulmonary edema, neurologic sxs. PAF w/ WPW, on AADs Compared w/ placebo, propafenone caused an increase in time to first recurrence of arrhythmia (p=0.004) PSVT: p=0.03 PAF: p=0.06 . Cardiac AEs occurred only in pts w/ PAF (9/11): 2 w/ prolonged episode of AF, 1 w/ atrial flutter w/ a mean ventricular rate of 263 bpm recorded using the telephone monitor. HR during recurrences, and not statistically different between propafenone and placebo N/A Propafenone efficacious in treating PSVT and PAF. Major limitation in not knowing how many pts had AVNRT. . 1994 (29) efficacy of (≥6 49 PSVT (n=21) PAF (n=28) Placebo Pts enrolled from 3 prior studies evaluating short-term flecainide efficacy Syncope, angina, or transient cerebral events during PSVT, second or third degree AV block or had CHF (NYHA -Number of pts w/o attacks -Time to first attack -Interval No pt experienced proarrhythmia, MI, or died during chronic efficacy study. N/A N/A Supports flecainide for chronic therapy of PSVT. d, blind, n
2015_SVT_Evidence_Tables_Data_Supplement.docx